Table 2.
Different mechanisms in regulating mRNA processes by IGF2BPs in cancers.
IGF2BPs | Cancer | Target mRNA | Mechanisms of IGF2BPs in RNA processes | Roles of mRNA in cancers | References |
---|---|---|---|---|---|
1 | Breast cancer | KRT7 | Serve as an m6A reader to promote mRNA stabilization | Promote breast cancer lunger metastasis | 10 |
1 | Lung adenocarcinoma | CTNNB1 | Promote mRNA stabilization | Oncogene | 101 |
1 | GC | SEC62 | Serve as an m6A reader to promote mRNA stabilization | Promote GC proliferation and inhibit cell apoptosis | 234 |
1 | CRC | β-TrCP1 | Prevent miRNA-dependent degradation | Serve as substrate recognition subunit of E3 ubiquitin ligase | 120 |
1 | CRC | LDHA | Bind to the 3′UTR of LDHA mRNA | Promote glycolysis | 171 |
1 | HCC | YES1 | Serve as an m6A reader to promote mRNA stabilization | Oncogene | 15 |
1 | HCC | LYPD1 | Stabilize mRNA in an m6A-dependent manner | Promote tumorigenesis | 122 |
1 | HCC | MKI67 | Promote mRNA stabilization | Promote cell proliferation and inhibit cell apoptosis | 235 |
1 | HCC | GLI1 | Promote mRNA stabilization | Promote cell proliferation and metastasis | 112 |
1 | HCC, ovarian cancer, lung cancer | SRF | Serve as an m6A reader and impair miRNA-dependent degradation | Enhance expression of genes that promote aggressive cancer phenotype | 11 |
1 | HCC, PC, ovarian cancer, melanoma, lung cancer, | E2F | Rely on 3′UTR-, miRNA-, and m6A-dependent to stabilize it | Promote G1/S cell cycle transition | 13 |
1 | Melanoma, ovarian cancer | eEF2 | \ | Enhance basal proliferation rates | 223 |
1 | Ovarian cancer | MDR1 | Promote mRNA stabilization | Regulate chemoresistance | 64 |
1 | Ovarian cancer | SIRT1 | Prevent miRNA-dependent degradation | Promote anoikis-resistance | 118 |
1 | Ovarian clear cell carcinoma | let-7 target mRNA (IGF2BP1, HMGA2, LIN28B) | Sequester mRNA into mRNP that do not contain RISC to stabilize it | Promote cancer cell growth and self-renewal | 116 |
1 | Endometrial cancer | SOX2 | Serve as an m6A reader to promote mRNA stabilization | An oncogenic transcriptional factor | 153 |
1 | Endometrial cancer | PEG10 | Serve as an m6A reader to promote mRNA stabilization | Promote cell cycle and cancer progression | 159 |
1 | Choriocarcinoma | RSK2, PPME1 | Promote mRNA stabilization | Promote cell migration and invasion | 236 |
1 | Osteosarcoma | c-MYC | Sequester mRNA into mRNP that do not contain RISC to stabilize it | Promote cancer cell proliferation | 7 |
1 | Seminoma | TFAP2C | Serve as an m6A reader to promote mRNA stabilization | Increase resistance to cisplatin | 163 |
1 | Breast cancer | E-cadherin, β-actin, α-actinin, Arp2/3 | Promote mRNA localization | Stabilize cell–cell connections and focal adhesions | 128 |
1 | Osteosarcoma, ovarian cancer | PTEN | Bind to a rare codon-comprising fragment of the PTEN ORF to stabilize it | Modulate cell polarization | 134 |
1 | Osteosarcoma, ovarian cancer, tumor-derived cells | MAPK4 | Inhibit mRNA translation through binding to MAPK4 3′UTR | Promote cell adhesion and migration | 134,237 |
1 | Rhabdomyosarcomas | cIAP1 | Promote mRNA translation | Mediate apoptotic resistance | 130 |
1 | HCC | HCV | Promote mRNA translation | \ | 131 |
1 | OSCC | BMI1 | Promote mRNA translation in an m6A-dependent manner | Promote cell proliferation and metastasis | 12 |
1/2/3 | cervical cancer, HCC | MYC | Serve as an m6A reader to promote mRNA stabilization | Promote cancer proliferation, migration, and invasion | 4 |
2 | HNSCC | SLUG | Serve as an m6A reader to promote mRNA stabilization | Lymphatic metastasis and EMT | 238 |
2 | PTC | APOE | Serve as an m6A reader to promote mRNA stabilization | Mediate glycolysis | 183 |
2 | Radioiodine-refractory papillary thyroid cancer | RUNX2 | Serve as an m6A reader to promote mRNA stabilization | Block the differentiation of radioiodine-refractory papillary thyroid cancer | 239 |
2 | Breast cancer | DROSHA | Serve as an m6A reader to promote mRNA stabilization | Maintain breast cancer stem-like cell stemness | 18 |
2/3 | LUAD | VANGL1 | Serve as an m6A reader to promote mRNA stabilization | Mitigate the effects of radiation on LUAD by increasing genes about DNA repair after the damage | 167 |
2 | Lung cancer | TK1 | Serve as an m6A reader to promote mRNA stabilization | Promote angiogenesis | 42 |
2 | GC | ZEB1 | LINC01559 recruits IGF2BP2 to stabilize ZEB1 mRNA | Serve as a transcription factor to combine with LINC01559, and promote cell proliferation, migration, and EMT | 94 |
2 | HCC | FEN1 | Serve as an m6A reader to promote mRNA stabilization | Promote HCC growth | 32 |
2 | PDAC | GLUT1 | Bind to the middle of GLUT1 mRNA and promote mRNA stabilization | Promote glycolysis and proliferation | 182 |
2 | CRC | KLF4 | Serve as an m6A reader to promote mRNA stabilization | A cancer suppressor gene; regulates intestinal epithelial homeostasis | 240 |
2 | CRC | SOX2 | Serve as an m6A reader to promote mRNA stabilization | Promote stemness features and metastatic | 152 |
2 | CRC | MTA1 | Serve as an m6A reader to promote mRNA stabilization | Promote cancer migration and invasion | 181 |
2 | CRC | RAF-1 | Prevent miRNA-dependent degradation | Promote cancer proliferation and survival | 121 |
2 | CRC | HK2 | Bind to the 5′UTR/3′UTR of HK2 mRNA as an m6A reader to promote mRNA stabilization | Promote glycolysis and proliferation | 185 |
2 | CRC | MSX1, JARID2 | LINC021 enhances its role as an m6A reader to promote mRNA stabilization | Promote tumorigenesis | 241 |
2 | Ovarian cancer | FGF9 | Promote mRNA stabilization | Induce chemoresistance and the polarization of TAMs toward the M2 phenotype | 104 |
2 | Prostate cancer | IGF1r | The mRNA stabilization may be related to m6A modification | Promotes bone metastasis and cancer growth | 96 |
2 | Prostate cancer | LDHA | Bind to the 3′UTR of LDHA mRNA to promote mRNA stabilization | Promote glycolysis | 93 |
2 | Malignant embryonic rhabdoid tumor, cervical cancer, breast cancer, HCC, CRC, lung cancer | HMGA1 | Bind to the 3′UTR of HMGA1 mRNA to promote mRNA stabilization and may be related to m6A modification | An oncogene; promote cancer proliferation, migration, and invasion | 81,105 |
2 | Glioblastoma | let-7 target mRNA (IGF2BP3, HMGA1, HMGA2, CCND1) | Prevent miRNA-dependent degradation | Preserve glioblastoma stem cell | 119 |
2 | Glioblastoma | CI/CIV | Promote the mRNA activity | Regulate OXPHOS | 137 |
2 | embryonic rhabdomyosarcoma | NRAS | Promote mRNA stabilization | oncogene | 242 |
2 | Embryonic rhabdomyosarcoma | IGF2 | Promote mRNA translation | \ | 80 |
2 | Radioiodine-refractory papillary thyroid cancer | ERBB2 | Increase translation efficacy through binding to the m6A methylation site | Contribute to acquired resistance to TKI | 133 |
3 | NPC | KPNA2 | Serve as an m6A reader to promote mRNA stabilization | Promote proliferation and metastasis | 40 |
1/3 | Cervical cancer | CD44 | Stabilize the 5.0 kb CD44 mRNA | Promote invadopodia formation | 129 |
3 | Breast cancer | CD44 | Regulate CD44 promoter activity | Promote cell proliferation, maintain stemness, and induce chemotherapy resistance | 179 |
3 | Breast cancer | PD-L1 | Serve as an m6A reader to promote mRNA stabilization | Inhibit cancer immune surveillance | 174 |
3 | Breast cancer | IGF2, MMP9, CD164 | Bind to the mRNA and promote mRNA stabilization | Involve in migration and invasion | 41 |
3 | Breast cancer | CERS6 | Promote mRNA stabilization | Promote cell proliferation, suppress cell apoptosis | 102 |
3 | Breast cancer | ABCG2 | Bind to ABCG2 mRNA and regulate its expression | Promote cell invasion | 243 |
3 | Esophageal cancer | KIF18A | Stabilize KIF18A mRNA | Promote cancer proliferation and migration and is associated with radioresistance | 244 |
3 | GC | HDGF | Serve as an m6A reader to promote mRNA stabilization | Secrete HDGF promotes cancer angiogenesis; nuclear HDGF increases glycolysis | 14 |
3 | GC | HIF1A | Serve as an m6A reader to promote mRNA stabilization | Promote cell migration and angiogenesis | 180 |
3 | HCC | pgRNA | Promote mRNA stabilization in an m6A-independent manner | Promote HCC proliferation, stemness, and tumorigenicity | 67 |
3 | HCC | TRAF5 | Promote mRNA stabilization | Promote cell proliferation and metastasis | 103 |
3 | CRC | KRAS, MAP2K1, TPR, CCNH | Promote mRNA stabilization with the help of ELAVL1 | Promote cancer proliferation | 245 |
3 | CRC | ABCB1 | Serve as an m6A reader to promote mRNA stabilization | Promote cancer chemoresistance | 246 |
3 | CRC | CCND1 | Serve as an m6A reader to promote mRNA stabilization | Promote cell cycle | 160 |
3 | CRC | VEGF | Serve as an m6A reader to promote mRNA stabilization | Promote angiogenesis | 160 |
2/3 | CRC | GLUT1 | Bind to 3′UTR of GLUT1 mRNA as an m6A reader | Promote glycolysis and proliferation | 185 |
3 | PDAC | HK2 | Promote mRNA stabilization | Participate glycolysis | 184 |
3 | Hematopoietic progenitor cell | CDK6, MYC | Stabilize the mRNA and/or enhance translation | Oncogene | 247 |
3 | ccRCC | CDK4 | Serve as an m6A reader to promote mRNA stabilization | Is associated with the G1/S transition | 95 |
3 | Cervical cancer, HCC | PDK4 | Serve as an m6A reader to promote mRNA stabilization | Promote glycolysis and ATP generation | 186 |
3 | Acute myeloid leukemia | COX2 | Bind to the 3′UTR of mRNA to promote mRNA stabilization | Inhibit cell apoptosis | 233 |
1/3 | Myeloid leukemia | MYC, BCL2 | Promote stability of m6A-modified mRNA with the help of YBX1 | Maintain the myeloid leukemia cell survival | 90 |
3 | AML | RCC2 | Serve as an m6A reader to promote mRNA stabilization | Promote AML progression | 248 |
3 | Human cancer cells | CCND1, CCND3, CCNG1 | Cooperate with HNRNPM to regulate post-transcriptional expression | Accelerate cell proliferation | 136 |
3 | Ewing sarcoma | CD164 | Bind to the mRNA to regulate its expression | Promote cancer invasion | 249 |
3 | Some kinds of solid cancers and fibrosarcoma | HMGA2, LIN28B | Sequester mRNA into mRNP that did not contain RISC | Oncogene | 117 |
3 | PDAC | 164 direct targe mRNA contained HMGA2, ZFP36L1, DCBLD2, CLDN1, CD44, ANTRX1, CLDN1, OLR1 | Bind to Ago2 (a RISC component) and act as a bi-modal regulator of mRNA stability | Promote cell migration, proliferation, and remodel focal adhesion | 123 |
3 | HCC | ZO-1 | Enhance Ago2-mRNA interactions to inhibit ZO-1 expression | Down-regulation of ZO-1 promotes cancer metastasis and invasion | 250 |
3 | LUAD | EIF4E-BP2 | Serve as an RNA-destabilizing factor to promote EIF4E-BP2 mRNA degradation | Promote EIF4E-mediated translation activation | 125 |
3 | CRC | ULBP2 | Bind to the 3′UTR of ULBP2 mRNA to destabilize it | Enable immune cells to recognize and destroy cells that express it | 124 |
2/3 | TNBC | PR | Recruit CNOT1 to destabilize PR mRNA | Promote the metastasis | 47 |
AML: acute myeloid leukemia; CRC: colorectal cancer; GC: gastric cancer; HCC: hepatocellular carcinoma; HNSCC: head and neck squamous cell carcinoma; LUAD: lung adenocarcinoma; NPC: nasopharyngeal carcinoma; OSCC, oral squamous cell carcinoma; PC, pancreatic cancer; PDAC: pancreatic ductal adenocarcinoma; PTC: papillary thyroid cancer; TNBC: triple-negative breast cancer.